Improved radiotracing of oxytocin receptor-expressing tumours using the new [111 In]-DOTA-Lys8-deamino-vasotocin analogue

British Journal of Cancer

Volumn 89, Issue 5, 2003, Pages 930-936

  Chini, B ^a   Chinol, M ^b   Cassoni, P ^c   Papi, S ^b   Reversi, A ^a   Areces, L ^b   Marrocco, T ^c   Paganelli, G ^b   Manning, M ^d   Bussolati, G ^c  

^a CNR   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

LVT; OT; Oxytcocin receptor; Radioligand; Tumours

Indexed keywords

OXYTOCIN; OXYTOCIN RECEPTOR; RADIOLIGAND; RECEPTOR SUBTYPE; TRACER; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOTOCIN[8 LYSINE DOTA INDIUM 111];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CHELATING AGENTS; COS CELLS; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; NEOPLASMS; OXYTOCIN; PROTEIN BINDING; RADIOACTIVE TRACERS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, OXYTOCIN; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TISSUE DISTRIBUTION; TRANSFECTION; TUMOR CELLS, CULTURED; VASOTOCIN;

EID: 0141507050     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601189     Document Type: Article

References (28)

1. Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Hibert M, Tribollet E, Manning M (1999) Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect 12: 279-292
2. Boissonnas RA, Huguenin RL (1960) Synthèse de la Lys8-oxytocine (lysine-vasotocine) et nouvelle synthèse de la lysine-vasopressine. Helv Chem Acta 43: 182-190
3. Buckley RG, Searle F (1984) An efficient method for labeling antibodies with 111In. FEBS Lett 166: 202-204
4. Bussolati G, Cassoni P, Ghisolfi G, Negro F, Sapino A (1996) Immunolocalization and gene expression of oxytocin receptors in carcinomas and non-neoplastic tissues of the breast. Am J Pathol 148: 1895-1903
5. Bussolati G, Chinol M, Chini B, Nacca A, Cassoni P, Paganelli G (2001) 111In-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴ -tetraacetic acid-lys(8)-vasotocin: a new powerful radioligand for oxytocin receptor-expressing tumors. Cancer Res 61: 4393-4397
6. Cassoni P, Sapino A, Negro F, Bussolati G (1994) Oxytocin inhibits proliferation of human breast cancer cell lines. Virchows Arch 425: 467-472
7. Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G (1998) Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. Int J Cancer 77: 695-700
8. Cassoni P, Sapino A, Munaron L, Deaglio S, Chini B, Graziani A, Ahmed A, Bussolati G (2001) Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. Endocrinology 142: 1130-1136
9. Cassoni P, Sapino A, Deaglio S, Bussolati B, Volante M, Munaron L, Albini A, Torrisi A, Bussolati G (2002) Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Res 62: 2406-2413
10. Chini B, Mouillac B, Ala Y, Balestre M, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, Barberis C (1995a) Tyr115 is the key residue for determining receptor selectivity in the V1a vasopressin receptor. EMBO J 14: 2176-2182
11. Chini B, Mouillac B, Ala Y, Balestre MN, Cotte N, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M et al. (1995b) Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family. Adv Exp Med Biol 395: 321-328
12. de Jong M, Krenning E (2002) New advances in peptide receptor radionuclide therapy. J Nucl Med 43: 617-620
13. Froidevaux S, Eberle AN (2002) Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66: 161-183
14. Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81: 629-683
15. Golubow J, du Vigneaud V (1963) Comparison of susceptibility of oxytocin and desamino-oxytocin to inactivation by leucine aminopeptidase and achymotrypsin. Proc Soc exp Biol 112: 218-219
16. Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M, Chini B (2002) Localisation of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene 21: 1658-1667
17. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H (1992) Structure and expression of human oxytocin receptor. Nature 356: 526-529
18. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M (1984) Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 142: 68-78
19. Merlo A, Hausmann O, Washer M, Steiner P, Otte A, Jermann E, Freitag P, Reubi JC, Muller-Brand J, Gratzl O, Macke HR (1999) Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phel-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5: 1025-1033
20. Novak JF, Judkins MB, Chernin MI, Cassoni P, Bussolati G, Nitche JA, Nishimoto SK (2000) A plasmin-derived hexapeptide from the carboxyl end of osteocalcin counteracts oxytocin-mediated growth inhibition [corrected] of osteosarcoma cells [published erratum appears in Cancer Res 2000 Aug 15;60(16):4663]. Cancer Res 60: 3470-3476
21. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yttrium-90-labeled somatostatin-analogue for cancer treatment. Lancet 351: 417-418
22. Paganelli G, Zoboli S, Cremonesi M, Macke HR, Chinol M (1999) Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phel-Tyr3-Octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm 14: 477-483
23. Pequeux C, Breton C, Hendrick JC, Hagelstein MT, Martens H, Winkler R, Geenen V, Legros JJ (2002) Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Cancer Res 62: 4623-4629
24. Peter J, Burbach H, Adan RA, Lolait SJ, van Leeuwen FW, Mezey E, Palkovits M, Barberis C (1995) Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol 15: 573-595
25. Rimoldi V, Reversi A, Taverna E, Rosa P, Francolini M, Cassoni P, Parenti M, Chini B (2003) Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene, in press
26. Rimpler M (1971) [1-Desamino]-lysinvasotocin, ein disulfidpolypeptid mit oxytocin-wirkkung. Justus Liebigs Ann Chem 745: 8-19
27. Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T (2002) Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V1a receptors. J Med Chem 45: 2579-2588
28. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, Smith AG, Gant TW (2001) Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20: 1300-1306